Biomarkers for diagnosing tuberculosis

Plasma protein markers such as EN-RAGE and MCP-3 were screened through Olink technology, and diagnostic kits for subclinical tuberculosis were developed, which solved the problem that the existing technology was difficult to diagnose subclinical tuberculosis, achieved efficient diagnostic performance, and ensured that The possibility of early intervention and treatment.

CN118914564AActive Publication Date: 2024-11-08BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411024591.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-08
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively diagnose subclinical tuberculosis, resulting in the infectious person not being discovered and treated in a timely manner, becoming a source of hidden transmission, and lacking biomarkers widely used in the diagnosis of subclinical tuberculosis.

Method used

Olink technology screened out the combination of plasma protein markers such as EN-RAGE and MCP-3, and developed kits for diagnosing subclinical tuberculosis, using the significant changes in these markers for diagnosis, providing tools such as ELISA, colloidal gold detection kits, etc. .

Benefits of technology

Significantly distinguished subclinical TB from healthy or latent infection samples, with AUC values ​​of up to 0.8-0.9 alone or in combination, ensuring high diagnostic efficacy, and high diagnostic specificity and sensitivity were also shown in the verification cohort.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914564A_ABST
    Figure CN118914564A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biomedicine, and particularly relates to a group of biomarkers for diagnosing subclinical tuberculosis. The invention discloses a group of biomarkers for diagnosing subclinical tuberculosis, a group of plasma protein marker combinations for diagnosing subclinical tuberculosis are screened out through an Olink technology, and the biomarkers can be used for remarkably distinguishing subclinical TB and healthy + LTBI samples. The compound has higher diagnosis efficiency on subclinical tuberculosis independently or in combination, and is beneficial to promoting early intervention and treatment of tuberculosis. Wherein the EN-RAGE and the EN-RAGE are used for independently diagnosing the AUC value gt; 0.8, and the AUC value of the EN-RAGE and MCP-3 combined diagnosis is 0.896.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a group of biomarkers for diagnosing subclinical tuberculosis. Background Art

[0002] Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M.tb). It is mainly transmitted through the air and poses a serious threat to global public health security. Although some progress has been made in the control of tuberculosis worldwide, its morbidity and mortality rates remain high. From infection with Mycobacterium tuberculosis to onset of the disease, the human body will go through four stages: infection clearance, latent infection, subclinical tuberculosis, and active tuberculosis (Li Meng, Gao Qian. Stage division of the natural history of tuberculosis and the current status and prospects of its diagnosis [J]. Chinese Journal of Anti-Tuberculosis, 2021, 43(11): 1125-1131.). Early diagnosis and timely treatment of tuberculosis are crucial to controlling its spread and reducing mortality.

[0003] Subclinical tuberculosis (S-TB) refers to the absence of obvious clinical symptoms in tuberculosis-infected patients, but the presence of tuberculosis infection can be detected through imaging, laboratory tests and other means. Studies have shown that in terms of age distribution, the proportion of subclinical tuberculosis patients aged ≥45 years is relatively high (Wang Hanfei, Li Tao, Zhao Yanlin, et al. Analysis of treatment outcomes and influencing factors of subclinical tuberculosis in China from 2021 to 2022 [J]. Tropical Diseases and Parasitology, 2023, 21(02): 72-77+92.). Subclinical tuberculosis plays a key role in the tuberculosis transmission chain, because its infected people are often not diagnosed and treated in time, thus becoming a hidden source of transmission. Although there are many studies on biomarkers for the diagnosis of subclinical tuberculosis, no biomarkers that can be widely used in the actual diagnosis of subclinical tuberculosis have been developed. Currently, there is no validated tool for diagnosing subclinical tuberculosis. Diagnosis mainly relies on etiological methods for diagnosing active tuberculosis (including chest X-ray, sputum acid-fast bacilli smear microscopy, mycobacterial culture and GeneXpert MTB / RIF, etc.). However, due to the relatively low amount of subclinical tuberculosis bacteria, it is not easy to be detected, which often leads to missed diagnosis (Wang Hanfei, Zhao Yanlin, Xu Caihong. Research progress on subclinical tuberculosis [J]. Chinese Journal of Anti-Tuberculosis, 2023, 45(08): 808-813.).

[0004] Proteomics technology can provide important molecular markers for the early diagnosis of diseases by large-scale analysis and identification of proteins and their modifications in organisms. In recent years, the application of proteomics technology in infectious disease research has gradually increased, especially in the search and verification of disease-related biomarkers. Olink technology is a high-throughput proteomics technology that combines protein amplification and probe-based immunoassay methods to achieve accurate quantitative analysis of multiple proteins in plasma. Olink technology has the advantages of high sensitivity and high specificity, and can maintain good performance in the detection of low-abundance proteins, making it suitable for the screening and verification of biomarkers. Summary of the invention

[0005] Through Olink technology, the present invention screened out a group of plasma protein markers for subclinical tuberculosis diagnosis, which showed significant changes in the plasma of subclinical tuberculosis patients, had strong diagnostic efficacy for subclinical tuberculosis diagnosis, and helped promote early intervention and treatment of tuberculosis. Based on this, the present invention was completed.

[0006] In a first aspect, the present invention provides a set of biomarkers for diagnosing subclinical tuberculosis, wherein the biomarkers are EN-RAGE and / or MCP-3.

[0007] Furthermore, the biomarkers are derived from the patient's blood.

[0008] In a second aspect, the present invention provides an application of a biomarker in the preparation of a reagent for diagnosing subclinical tuberculosis, wherein the biomarker is one or more of EN-RAGE and MCP-3, and the reagent contains a reagent that can detect the content of EN-RAGE and MCP-3 in a patient's biological sample; when the content of EN-RAGE and / or MCP-3 increases, it indicates subclinical tuberculosis.

[0009] Furthermore, the biological sample is selected from patient blood.

[0010] In a third aspect, the present invention provides a kit for diagnosing subclinical tuberculosis, the kit comprising reagents for detecting the content of EN-RAGE and MCP-3 in a patient's biological sample; when the content of EN-RAGE and / or MCP-3 is elevated, it indicates subclinical tuberculosis.

[0011] Furthermore, the kit may be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

[0012] Furthermore, the diagnostic method of the kit includes one or more of a direct method, an indirect method, a double antibody sandwich method and / or a competitive method.

[0013] Beneficial Effects

[0014] The biomarkers screened by the present invention can significantly distinguish subclinical TB and healthy + LTBI samples, and have high diagnostic efficacy for subclinical tuberculosis alone or in combination. Among them, the AUC values ​​of EN-RAGE and EN-RAGE alone in the screening cohort are both >0.8, and the AUC value of the combined diagnosis of EN-RAGE and MCP-3 is 0.896; the AUC values ​​of EN-RAGE and EN-RAGE alone in the validation cohort are both >0.6, and the AUC value of the combined diagnosis of EN-RAGE and EN-RAGE is 0.838. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 Schematic diagram of blood stratification after centrifugation.

[0016] Figure 2 This is a principal component analysis (PCA) diagram of protein expression levels in the screening cohort. Points of different colors represent the distribution of proteomics data of different populations. The horizontal axis is the first principal component (PC1) and the vertical axis is the second principal component (PC2).

[0017] Figure 3 The expression levels of differentially expressed proteins in the screening cohort. Note: A. EN-RAGE expression level; B. MCP-3 expression level.

[0018] Figure 4 Diagnostic efficacy analysis of differentially expressed proteins in the screening cohort. Note: A. Diagnostic efficacy of EN-RAGE; B. Diagnostic efficacy of MCP-3; C. Combined diagnostic efficacy of EN-RAGE and MCP-3.

[0019] Figure 5 To verify the expression level of differentially expressed proteins in the cohort. Note: A. EN-RAGE expression level; B. MCP-3 expression level.

[0020] Figure 6 To verify the diagnostic efficacy of differentially expressed proteins in the cohort. Note: A. Diagnostic efficacy of EN-RAGE; B. Diagnostic efficacy of MCP-3; C. Combined diagnostic efficacy of EN-RAGE and MCP-3. DETAILED DESCRIPTION

[0021] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0022] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0023] The "EN-RAGE" described in the present invention is a new member of the calgranulin superfamily, also known as S100A12 and MRP6, which is mainly synthesized and secreted by granulocytes and plays a key role in regulating immune responses and inflammatory processes. As a pro-inflammatory factor, EN-RAGE can specifically bind to RAGE and activate downstream signal transduction pathways, including NF-KB and MAP kinase. Studies have shown that the expression level of serum S100A12 in patients with RA and systemic lupus erythematosus is significantly higher than that in the healthy control group. The same phenomenon also occurs in patients with chronic obstructive pulmonary disease (COPD).

[0024] The "MCP-3" mentioned in the present invention refers to monocyte chemoattractant protein-3, which is a kind of basic protein produced by cells with multiple biological functions. It acts on endothelial cells, promotes cell proliferation and migration, and positively regulates angiogenesis. MCP-3 is a powerful chemokine for various cells and can bind to various chemokine receptors, such as CC chemokine receptors CCR 1, CCR 2, CCR 3, CCR 5 and CCR 10. Its binding can activate multiple signaling pathways, thereby affecting the occurrence and development of tumors.

[0025] Example 1 Screening of differentially expressed proteins in subclinical tuberculosis based on Olink proteomics technology

[0026] 1. Experimental subjects

[0027] The subjects were divided into healthy elderly group, latent tuberculosis infection (LTBI) elderly group and subclinical elderly TB group.

[0028] According to the inclusion and exclusion criteria, 45 samples (15 healthy elderly people, 15 elderly people with LTBI, and 15 elderly patients with subclinical TB) were recruited from the Guangxi Zhuang Autonomous Region Chest Hospital as a screening cohort, and the participants signed informed consent.

[0029] 2. Inclusion criteria

[0030] Healthy elderly people: aged ≥60 years; IGRA negative; no other serious medical history.

[0031] LTBI elderly: age ≥ 60 years; IGRA positive; no other serious medical history.

[0032] Subclinical elderly TB patients: age ≥ 60 years; IGRA positive; laboratory diagnosis of TB; mild condition; sputum but no clinical symptoms; no extrapulmonary tuberculosis; no other serious medical history.

[0033] Exclusion criteria: HIV-coinfected individuals and individuals with other comorbidities, and anyone with an indeterminate IGRA result.

[0034] 3. Sample collection

[0035] 1) Collect 5 mL of peripheral blood from the subject.

[0036] 2) Take 3-4 mL of mononuclear cell separation solution and add it to the centrifuge tube. Use a pipette to draw up the blood sample and add it to the surface of the separation solution. Adjust the ascending speed to 8 and descending speed to 6, and centrifuge at 600g for 25 minutes.

[0037] 3) After centrifugation, the centrifuge tube is divided into four layers from top to bottom ( Figure 1 ). The first layer is the plasma layer, the second layer is the ring-shaped milky white mononuclear cell layer, the third layer is the transparent separation fluid layer, and the fourth layer is the red blood cell layer.

[0038] 4) Take the upper plasma layer and package it, record the patient's name, hospital number, and date, and store the samples at -80℃.

[0039] 4. Identification of differentially expressed markers by plasma Olink proteomics

[0040] Proteomic analysis of the plasma samples collected above was performed using Olink technology to identify differentially expressed markers associated with subclinical tuberculosis. The specific experimental steps are as follows:

[0041] 4.1 Sample Randomization

[0042] Use the RAND function in the Excel table to generate a random value for each sample, and then arrange the values ​​from small to large so that the samples are randomly distributed in the 96-well plate.

[0043] 4.2 Sample collection

[0044] According to the randomized sample distribution table, 10-40 μL of each sample was placed in a 96-well plate.

[0045] External control: add 5 μL of mixed plasma sample to wells A12 and B12 respectively; add 5 μL of negative control (NC) to wells C12, D12, and E12 respectively; add 5 μL of interplate control (IPC) to wells F12, G12, and H12 respectively.

[0046] 4.3 Hybridization incubation

[0047] Preparation of hybridization mixture: Take out the reagents and thaw at room temperature. After vortexing and centrifuging, add 280μL of IncubationSolution, 40μL of Incubation Stabilizer, 40μL of A-probes, and 40μL of B-probes to a nuclease-free centrifuge tube in sequence, vortex and centrifuge. Add 47μL of hybridization mixture to each well in the 8-tube strip. Mark the 96-well plate as an incubation plate, use an 8-channel pipette to add 3μL of hybridization mixture to each well, and then add 1μL of sample to each well. After sealing with sealing film, centrifuge at 400g for 1min, put it in a PCR instrument, set to 4℃∞, and incubate for 16-24h.

[0048] 4.4 Extension and Amplification

[0049] Set the PCR program: 50℃20min, 95℃5min, 95℃30s, 54℃1min, 60℃1min for 17 cycles; maintain at 10℃. Preparation of extension amplification mixture: Add 9385μL of High Purity Water, 1100μL of PEA Solution, 55μL of PEAEnzyme, and 22μL of PCR Polymerase to the centrifuge tube in sequence, vortex and centrifuge. Remove the incubation plate from the PCR instrument and centrifuge, add 96μL of extension amplification mixture to each well, seal the film, vortex and centrifuge, place it on the PCR instrument preheated at 50℃, and resume the program.

[0050] 4.5 Chip Pretreatment

[0051] Take out the chip, press the piston hole in the syringe, and push the liquid in. Click the instrument Target 96 option, put in the chip and cover, and click to start chip pretreatment.

[0052] 4.6 Computer Operation

[0053] Prepare the detection mixture: add 550μL of Detection Solution, 230μL of High Purity Water, 7.8μL of Detection Enzyme, and 3.1μL of PCR Polymerase to the centrifuge tube in sequence, vortex and centrifuge. Dispense 95μL per well into the tube strips. Take out the 96-well plate and add 7.2μL of the mixture to each well. After the extension amplification program is completed, add 2.8μL of product to each well, vortex and mix for later use. Prepare the diluted sample plate, primer plate, and pre-treated chip. Add 5μL of primers to the left side of the chip and 5μL of diluted product to the right side to avoid bubbles. After the sample addition is completed, put it into the sample loading station, set the run name, and click Run.

[0054] 4.7 Data Analysis and Export

[0055] After the instrument is shut down, export the run name file, open the OlinkNPX Signature 1.5.3.0 software, import the corresponding file, set the reagent panel information, reagent version number, and sample name, click "OK", and the software will automatically analyze and output the NPXExcel document and QCAR PDF document.

[0056] 4.8 Quality Control Analysis

[0057] Quality control analysis includes two aspects: QC_distribution and QC_IQR. In QC_distribution, the parallelism of quality control tests between samples is evaluated by statistically analyzing the internal quality control values ​​of each sample. The distribution of quality control values ​​is represented by five statistics, namely the maximum value, upper quartile, median, lower quartile and minimum value. If some samples have deviations during the test, the quality control analysis will mark these samples and prompt a warning (Warning), but these samples are not excluded by default. In QC_IQR analysis, the degree of deviation of quality control tests between samples is evaluated by calculating the interquartile range (IQR) of the internal quality control values ​​of each sample. If the quality control values ​​of the samples are evenly distributed, it means that the test is relatively stable; if the quality control values ​​of the samples deviate greatly, it means that there is a certain variability in the test, but if the protein concentration is within the linear range, these samples can still be retained in the actual analysis. The quality control analysis will also mark the samples with deviations and prompt a warning.

[0058] 5. Results

[0059] 5.1 Screening of differentially expressed proteins

[0060] By comparing the protein expression levels of three groups of people: healthy elderly people, LTBI elderly people and subclinical elderly TB patients, the markers with significant differential expression were screened. Figure 2The results of dimensionality reduction of proteomic data of the three groups of people by principal component analysis (PCA) are shown. There are significant differences in the distribution of proteomic data among the three groups of people. The most significantly differentially expressed markers (EN-RAGE and MCP-3) were selected for further analysis. One-way ANOVA and multiple comparisons were used to determine the statistical significance among the three groups (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001) using graphpad software.

[0061] The expression levels of EN-RAGE and MCP-3 proteins in the subclinical elderly TB patients were significantly different from those in the healthy elderly and LTBI elderly groups, but there was no significant difference between the healthy elderly and LTBI elderly groups ( Figure 3 AB).

[0062] 5.2 Analysis of diagnostic efficacy of differentially expressed markers

[0063] The expression levels of EN-RAGE and MCP-3 plasma proteins in the subclinical elderly TB group and the healthy elderly + LTBI elderly group were compared and analyzed based on ROC.

[0064] The results showed that EN-RAGE had a significant ability to distinguish subclinical TB from healthy + LTBI samples, with an AUC value of up to 0.856 (95% confidence interval, 0.719-0.942; sensitivity, 80%; specificity, 86.67%) ( Figure 4 A). MCP-3 has a significant ability to distinguish subclinical TB from healthy + LTBI samples, with an AUC value as high as 0.863 (95% confidence interval, 0.728-0.947; sensitivity, 93.33%; specificity, 66.67%) ( Figure 4 B).

[0065] Furthermore, the differentially expressed proteins EN-RAGE and MCP-3 were combined to evaluate their combined diagnostic efficacy. A combined diagnostic model was constructed through multivariate logistic regression analysis, and the ROC curve of combined diagnosis was drawn.

[0066] like Figure 4 As shown in Figure C, the AUC value of the combined marker was as high as 0.896 (95% confidence interval, 0.768-0.967; sensitivity, 86.7%; specificity, 86.7%), which was higher than that of a single marker and had a higher specificity, indicating that the combined diagnostic efficacy was better. Example 2 Verification of EN-RAGE and MCP-3 expression levels in plasma of elderly patients with different Mtb infection states 1. Sample selection

[0067] The subjects included healthy elderly people, elderly people with LTBI, and elderly people with subclinical TB. Thirty participants from the Guangxi Zhuang Autonomous Region Chest Hospital were selected from each group, and a total of 90 subjects were used as the validation cohort. Plasma samples from each participant were collected according to the method described in Example 1 for subsequent experiments.

[0068] 2. Source of ELISA kit

[0069] EN-RAGE and MCP-3 ELISA kits were provided by ELISA company. ELISA kit (EN-RAGE): Catalog number LD13698, 96T / box; ELISA kit (MCP-3) Catalog number: LD10478, 96T / box. All kits were operated according to the instructions provided by the manufacturer, and the performance of the kits was verified before the experiment to ensure the reliability and consistency of the experimental results.

[0070] 3. ELISA verification

[0071] ELISA experiments were performed using the specific antibodies of the markers EN-RAGE and MCP-3 screened in Example 1.

[0072] According to the standard ELISA operation process, the expression levels of EN-RAGE and MCP-3 markers in each plasma sample were detected. The specific steps include sample dilution, sample loading, incubation, washing, addition of enzyme-labeled secondary antibody, re-incubation, termination of reaction and plate reading. The detection of each sample was repeated at least three times to ensure the accuracy and repeatability of the data. The expression of each marker in different groups was recorded.

[0073] 4. Data Analysis

[0074] One-way ANOVA and multiple comparisons were used to determine the statistical significance among the three groups using graphpad software. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, validating the biomarkers for diagnosis of subclinical elderly TB patients.

[0075] 5. Results

[0076] like Figure 5 As shown in the figure, the subclinical elderly TB group had significant differences in EN-RAGE and MCP-3 plasma expression levels compared with the healthy elderly and LTBI elderly groups, but there was no significant difference between the healthy elderly and LTBI elderly groups. The diagnostic efficacy of EN-RAGE and MCP-3 in the subclinical elderly TB group and the healthy elderly + LTBI elderly group was further verified based on ROC comparison. Figure 6As shown, the AUC value of EN-RAGE was 0.638 (95% confidence interval, 0.530-0.737; sensitivity, 56.7%; specificity, 78.3%) ( Figure 6 A). The AUC value of MCP-3 was 0.701 (95% confidence interval, 0.595-0.793; sensitivity, 50%; specificity, 90%) ( Figure 6 B) EN-RAGE and MCP-3 were further combined to evaluate their combined diagnostic efficacy. A combined diagnostic model was constructed through multivariate logistic regression analysis, and the ROC curve of combined diagnosis was drawn. Figure 6 As shown in Figure C, the AUC value of the combined marker was as high as 0.838 (95% confidence interval, 0.745-0.907; sensitivity, 56.7%; specificity, 100%). The results verified the diagnostic efficacy of the marker combination in expanding clinical samples and confirmed its feasibility in actual clinical diagnosis.

Claims

1. A set of biomarkers for diagnosing subclinical tuberculosis, wherein the biomarkers are EN-RAGE and / or MCP-3.

2. The biomarker for diagnosing subclinical tuberculosis according to claim 1, wherein the biomarker is derived from the patient's blood.

3. Use of a biomarker in the preparation of a reagent for diagnosing subclinical tuberculosis, wherein the biomarker is one or more of EN-RAGE and MCP-3, and the reagent is a reagent that can detect the content of EN-RAGE and MCP-3 in a patient's biological sample; when the content of EN-RAGE and / or MCP-3 is elevated, it indicates subclinical tuberculosis.

4. A kit for diagnosing subclinical tuberculosis, the kit comprising reagents for detecting the content of EN-RAGE and MCP-3 in a patient's biological sample; when the content of EN-RAGE and / or MCP-3 is elevated, it indicates subclinical tuberculosis.

5. The kit for diagnosing subclinical tuberculosis according to claim 4, wherein the kit can be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

6. A kit for diagnosing subclinical tuberculosis according to any one of claims 4 or 5, wherein the diagnostic method of the kit comprises one or more of a direct method, an indirect method, a double antibody sandwich method and / or a competitive method.

Citation Information

Patent Citations

  • Circulating biomarkers

    CN103492590A